Methyldopa hydrate

Cat. No.: HY-B0225B

CAS No.: 41372-08-1 Molecular Formula: C₁₀H₁₆NO_{5.5}

Molecular Weight: 238.24

Target: Adrenergic Receptor; Endogenous Metabolite

Pathway: GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years

4°C 2 years

-80°C In solvent 6 months

> -20°C 1 month

1.5H₂O

SOLVENT & SOLUBILITY

In Vitro

DMSO: 25 mg/mL (104.94 mM; Need ultrasonic) H₂O: 1 mg/mL (4.20 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.1974 mL	20.9872 mL	41.9745 mL
	5 mM	0.8395 mL	4.1974 mL	8.3949 mL
	10 mM	0.4197 mL	2.0987 mL	4.1974 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution

BIOLOGICAL ACTIVITY

Description Methyldopa hydrate (L-(-)- α -Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective

for α 2-adrenergic receptors). Methyldopa hydrate is a proagent and is metabolized (α -Methylepinephrine) in the central

 $nervous\ system^{[1][2]}.$

IC₅₀ & Target α adrenergic receptor

In Vivo

Methyldopa hydrate (L-(-)- α -Methyldopa hydrate; 200 mg/kg; i.p.) decreases the hyperglycemic response in the first 2 hr after Dieldrin treatment^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	60-day-old male rats ^[2]	
Dosage:	200 mg/kg	
Administration:	i.p.	
Result:	Decreased the plasma concentration of glucose in Dieldrin-exposed rats by 24% during the 30 min following its administration.	

CUSTOMER VALIDATION

• Clin Chem. 2019 Dec;65(12):1522-1531.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sweet CS. New centrally acting antihypertensive drugs related to methyldopa and clonidine. Hypertension. 1984;6(5 Pt 2):II51-II56.

[2]. Fox GR, et al. The effects of phenobarbital, atropine, L-alpha-methyldopa, and DL-propranolol on dieldrin-induced hyperglycemia in the adult rat. Toxicol Appl Pharmacol. 1985;78(3):342-350.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA